Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 11/20 | 0.71 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.63 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.48 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.48 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3618364 | 0.87 | CHEK1 (0.84) | IKBKBCHEK1MEN1KMT2A | |
| SCHEMBL1383137 | 0.83 | IKBKB (1.00) | IKBKBCHEK1MAP3K7KDM4EALDH1A1 | |
| SCHEMBL3607420 | 0.83 | CHEK1 (0.74) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3612524 | 0.82 | IKBKB (0.63) | IKBKBCHEK1MAP3K7KDM4E | |
| SCHEMBL1385004 | 0.82 | IKBKB (1.00) | IKBKBCHEK1MAP3K7KDM4EALDH1A1 | |
| SCHEMBL3612210 | 0.81 | CHEK1 (0.65) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3610863 | 0.78 | IKBKB (0.60) | IKBKBCHEK1MAP3K7 | |
| SCHEMBL3612027 | 0.78 | CHEK1 (1.00) | IKBKBCHEK1MEN1KMT2A | |
| SCHEMBL3614444 | 0.77 | IKBKB (0.68) | IKBKBCHEK1MAP3K7HDAC1 | |
| SCHEMBL3611798 | 0.76 | MAP3K7 (0.61) | IKBKBCHEK1MAP3K7HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | ASTRAZENECA AB (SW) | 2010-02-04 | — | — | US | disclosed |
| US-7572826-B2 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme IKK-2 | ASTRAZENECA AB (SE) | 2009-08-11 | — | — | US | disclosed |
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | ASTRAZENECA AB (SE) | 2006-03-16 | — | — | US | disclosed |
| EP-1583755-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | AstraZeneca AB (SE) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004063186-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZIME IKK-2 | ASTRAZENECA AB (SE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058522-A1 | Thiophene-carboxamide derivatives and their use as inhibitors of the enzyme ikk-2 | NFKBIA, RELA, IKBKE | IKBKB 5/4885CHEK1 487/4885MAP3K7 129/4885 |
| US-20100029754-A1 | THIOPHENE-CARBOXAMIDE DERIVATIVES AND THEIR USE AS INHIBITORS OF THE ENZYME IKK-2 | NFKBIA, RELA, IKBKE | IKBKB 5/4885CHEK1 487/4885MAP3K7 129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.